Source: Annual Congress 2009 - Treatment beyond inhalers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Shah, J. Fiterman, R. Niven (London, Manchester, United Kingdom; Porto Alegre, Brazil). Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial. Eur Respir J 2009; 34: Suppl. 53, 1830

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Safety profile of glycopyrronium in patients with COPD: An innovative approach to analyse data from post-marketing surveillance (PMS) Source: International Congress 2014 – Asthma and COPD management Year: 2014 QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Practice-related treatment of severe persistent bronchial asthma using omalizumab in Germany: the compliance and utilisation investigation under real-life-study (XCLUSIVE) Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016